Food intake and rumen motility in dwarf goats. Effects of atipamezole on the inhibitory effects induced by detomidine, medetomidine and romifidine

Postanaesthetic effects of ketamine-midazolam and ketamine-medetomidine on gastrointestinal transit time in rabbits anaesthetised with isoflurane

BACKGROUND

Gastrointestinal stasis is a common perianaesthetic complication in rabbits. The objective of this study was to assess the impact on gastrointestinal transit time of ketamine-midazolam (KMZ) versus ketamine-medetomidine (later antagonised by atipamezole) (KMT-A) in rabbits anaesthetised with isoflurane.

METHODS

This was a cross-over, randomised, single-blinded, controlled, experimental trial. Seven healthy adult New Zealand White rabbits were used. Gastrointestinal transit time was assessed by contrast radiography in awake rabbits. Presence of contrast medium in the small intestine (gastric transit time), in the caecum (small intestinal transit time) and in faeces in the colon was assessed. One week later, 55 minutes isoflurane anaesthesia was induced with ketamine (15 mg/kg) and either midazolam (3 mg/kg) or medetomidine (0.25 mg/kg) by intramuscular injection. Thirty minutes after discontinuation of isoflurane, atipamezole (0.5 mg/kg) was administered only to rabbits in KMT-A treatment. Gastrointestinal transit time was then assessed in both treatment groups, beginning 30 minutes after cessation of isoflurane administration. Two weeks later, the treatment groups were interchanged.

RESULTS

Gastric and small intestinal transit times were significantly longer with KMT-A (92±109 minutes and 214±119 minutes, respectively) than with KMZ (1±0 minutes and 103±6 minutes, respectively) and in the awake state (7±7 minutes and 94±32 minutes, respectively).

CONCLUSION

Clinicians should therefore be aware of the potential gastrointestinal side effects of KMT-A, particularly in rabbits at risk for gastrointestinal stasis.

Effect of fescue toxicosis on whole body energy and nitrogen balance, in situ degradation and ruminal passage rates in Holstein steers

This study was designed to examine alteration of ruminal kinetics, as well as N and energy balance during fescue toxicosis. Six ruminally cannulated Holstein steers (bodyweight (BW) = 217 ± 7 kg) were weight matched into pairs and pair fed throughout a crossover design experiment with a 2×2 factorial treatment structure. Factors were endophyte (infected, E+ vs. uninfected, E−) and feeding level (1100 (L) or 1800 (H) kJ/kG BW.75). During each period, after 8 days of feeding level adaptation, animals were ruminally dosed twice daily with ground fescue seed for the remainder of the period. One steer per pair was dosed with ground endophyte infected fescue seed (E+), the other with ground endophyte free fescue seed. In situ degradation of ground alfalfa was determined on Days 13–16. Total faecal and urinary collections were performed on Days 17–21, with animals placed into indirect calorimetry head-boxes during Days 20 and 21. Heat production (HP) was calculated using the Brower equation. Retained energy (RE) was calculated as intakeE – (faecalE + urinaryE + gaseousE + HP). Liquid and particulate passage rates were evaluated using Cr:EDTA and iADF respectively on Days 22 and 23. There was no difference (P > 0.9) in dry matter intake (DMI)/kg.75 between endophyte treatments, and DMI/kg.75 was different (P < 0.01) between H and L intake by design. Animals on H feeding had higher (P < 0.01) water, N and energy intakes. Energy and N excretion, as well as retained DE, ME, RE, and HP were higher (P < 0.03) for H versus L. There was no difference in retained N, DE, ME, or HP (P > 0.15) between endophyte treatments. Neither rate nor extent of in situ degradation was altered by intake level or endophyte treatment (P > 0.3). DM percentage and DM weight of rumen contents were increased (P < 0.01) by E+ dosing. Particulate passage increased (P = 0.0002) during H intake and decreased (P = 0.02) with E+ dosing. Ruminal liquid passage decreased (P < 0.03) with H feeding, while liquid flow rate tended to be reduced (P < 0.14) with E+ dosing. Total VFA concentration increased with both H feeding (P < 0.01) and E+ dosing (P < 0.0001). Despite these differences, the N and energy balance data indicate that the reductions in weight gain and productivity seen during fescue toxicosis are primarily due to reduced intake.

Alteration of fasting heat production during fescue toxicosis in Holstein steers

This study was designed to examine alteration of fasting heat production (FHP) during fescue toxicosis. Six ruminally cannulated Holstein steers (BW = 348 ± 13 kg) were BW-matched into pairs and used in a 2 period crossover design experiment. Each period consisted of 2 temperature segments, one each at 22 and 30°C. During each period, 1 steer per pair was ruminally dosed twice daily with 0.5 kg of ground endophyte-infected fescue seed (E+) and the other with ground endophyte-free fescue seed (E-) for 7 d. Steers on E- treatment were pair-fed to E+ steers offered alfalfa cubes at 1.5 × NEm. On d 8 of each segment, steers were moved to individual metabolism stalls fitted with indirect calorimetry head boxes. Ruminal contents were removed, weighed, and subsampled for DM determinations. The reticulorumen was washed and filled with a buffer (NaCl = 96; NaHCO3 = 24; KHCO3 = 30; K2HPO4 = 2; CaCl2 = 1.5; MgCl2 = 1.5 mmol·kg buffer(-1)) that was gassed with a 75% N2 and 25% CO2 mixture before rumen incubation. During buffer incubation, an E+ or E- fescue seed extract was added at 12 h intervals to maintain treatment presentation to the animal. After a 12-h wait, heart rate, O2 consumption, CO2 production, and urinary output were recorded for 16 h. There was no difference (P = 0.931) in DMI/kg(0.75) between endophyte treatments by design; however, intake decreased (P = 0.004) at 30°C. Increased temperature had no effect (P > 0.10) on other measurements and there were no significant interactions (P > 0.11) of temperature and endophyte treatment. Heart rate was unaffected by fescue treatment or environmental temperature. Percent DM of ruminal contents as well as total rumen DM/kg(0.75) was increased (P < 0.0001) in E+ steers. Respiratory quotient was elevated (P = 0.02) in E+ steers. Oxygen consumption decreased (P = 0.04) and CO2 production tended to be reduced (P = 0.07) during E+ treatment. Calculated FHP (kcal/kg BW(0.75)) was also less (P = 0.006) in steers receiving E+ treatment. These data suggest that consumption of endophyte-infected tall fescue by cattle results in a reduction in basal metabolic rate.

Sedative and analgesic effects of romifidine in camels (Camelus dromedarius)

OBJECTIVE

To evaluate the clinical effectiveness and the sedative and analgesic effects of intravenous (IV) romifidine in camels.

STUDY DESIGN

Randomized prospective study.

ANIMALS

Eighteen healthy adult Dromedary camels.

METHODS

Romifidine was administered IV to camels (n = 6) at three different doses (40, 80 or 120 microg kg(-1)). Time of onset, degree and duration of sedation and analgesia were recorded immediately after drug administration. Heart rate, respiratory rate, ruminal contractions, muscle relaxation, response to auditory and tactile stimulation, distance between ears, distance from lower lip to the ground, and degree of ataxia were also recorded pre-administration and at 5, 15, 30, 45, 60, 90, 120 and 180 minutes post-administration. Plasma glucose, blood urea nitrogen and creatinine were measured.

RESULTS

Romifidine produced dose dependent sedation and analgesia. Significant decreases in heart rate (p < 0.001), ruminal contractions (p < 0.05), distance from lower lip to the ground (p < 0.001), response to auditory and tactile stimuli (p < 0.01), and significant increases in the degree of ataxia (p < 0.01), distance between the ear tips (p < 0.001) and blood glucose (p < 0.01) concentration were recorded after administration of romifidine until recovery. However, no significant changes in rectal temperature and respiratory rate were recorded.

CONCLUSIONS AND CLINICAL RELEVANCE

Intravenous administration of romifidine at three different doses appeared to be an effective sedative and analgesic agent for camels. Bradycardia, ruminal atony, and hyperglycemia were the most important adverse effects after IV administration of romifidine. The IV administration of romifidine at a dose rate of 120 microg kg(-1) caused profound sedation and analgesia. Romifidine could be used for chemical restraint for a variety of diagnostic and minor surgical procedures in camels.

mRNA expression and binding sites for alpha2-adrenergic receptor subtypes in muscle layers of the ileum and spiral colon of dairy cows

OBJECTIVE

To measure maximum binding capacity (B(max)) and levels of mRNA expression for alpha(2)-adrenergic receptor (AR) subtypes in ileal and colonic muscle layers of healthy dairy cows.

SAMPLE POPULATION

Ileal and colonic muscle specimens from 6 freshly slaughtered cows.

PROCEDURES

Ileal and colonic muscle layers were obtained by scraping the mucosa and submucosa from full-thickness tissue specimens. Level of mRNA expression for alpha(2)-AR subtypes was measured by real-time reverse transcriptase-PCR analysis and expressed relative to the mean mRNA expression of glyceraldehyde phosphate dehydrogenase, ubiquitin, and 18S ribosomal RNA. Binding studies were performed with tritiated RX821002 ((3)H-RX821002) and subtype-selective ligands as competitors.

RESULTS

mRNA expression for alpha(2AD)-, alpha(2B)-, and alpha(2C)-AR subtypes was similar in ileal and colonic muscle layers. The mRNA expression for alpha(2AD)-AR was significantly greater than that for alpha(2B)- and alpha(2C)-AR subtypes, representing 92%, 6%, and 2%, respectively, of the total mRNA. Binding competition of (3)H-RX821002 with BRL44408, imiloxan, and MK-912 was best fitted by a 1-site model. The B(max) of alpha(2AD)- and alpha(2C)-AR sub-types was greater than that of alpha(2B)-AR. The B(max) and level of mRNA expression were only correlated (r = 0.8) for alpha(2AD)-AR. Ratio of B(max) to mRNA expression for alpha(2C)-AR was similar to that for alpha(2B)-AR, but significantly greater than for alpha(2AD)-AR.

CONCLUSIONS AND CLINICAL RELEVANCE

Subtypes of alpha(2)-AR in bovine intestinal muscle layers are represented by a mixture of alpha(2AD)- and alpha(2C)-ARs and of alpha(2B)-AR at a lower density. Information provided here may help in clarification of the role of AR subtypes in alpha(2)-adrenergic mechanisms regulating bovine intestinal motility.

Quantitative mRNA analysis of adrenergic receptor subtypes in the intestines of healthy dairy cows and dairy cows with cecal dilatation-dislocation

OBJECTIVE

To investigate the distribution of mRNA coding for 9 adrenoceptor subtypes in the intestines of healthy dairy cows and cows with cecal dilatationdislocation (CDD).

SAMPLE POPULATION

Full-thickness specimens of the intestinal wall were obtained from the ileum, cecum, proximal loop of the ascending colon (PLAC), and external loop of the spiral colon (ELSC) of 15 cows with CDD (group 1) and 15 healthy (control) cows (group 2, specimens collected during laparotomy; group 3, specimens collected after slaughter).

PROCEDURES

Concentrations of mRNA for 9 adrenoceptor subtypes (alpha(1A), alpha(1B), alpha(1D), alpha(2AD), alpha(2B), alpha(2C), beta(1), beta(2), and beta(3)) were measured by quantitative real-time reverse transcriptase-PCR assay. Results were expressed relative to mRNA expression of a housekeeping gene.

RESULTS

Expression of mRNA for alpha(1B)-, alpha(2AD)-, alpha(2B)-, beta(1)-, and beta(2)-adrenoceptors was significantly lower in cows with CDD than in control cows. In the ileum, these receptors all had lower mRNA expression in cows with CDD than in control cows. The same effect was detected in the ELSC for mRNA for alpha(2AD)-, alpha(2B)-, beta(1)-, and beta(2)-adrenoceptors, and in the cecum and PLAC for alpha(2B)- and beta(2)-adrenoceptors. Groups did not differ significantly for alpha(1A)-adrenoceptors. The mRNA expression for alpha(1D)-, alpha(2C)-, and beta(3)-adrenoceptors was extremely low in all groups.

CONCLUSIONS AND CLINICAL RELEVANCE

Differences in expression of mRNA coding for adrenoceptors, most pronounced in the ileum and spiral colon, between cows with CDD and control cows support the hypothesis of an implication of adrenergic mechanisms in the pathogenesis of CDD in dairy cows.

Distribution of mRNA that codes for subtypes of adrenergic receptors in the gastrointestinal tract of dairy cows

OBJECTIVE

To describe the distribution of mRNA that codes for 9 subtypes of adrenergic receptors in the digestive tract of dairy cows.

SAMPLE POPULATION

Fresh full-thickness wall specimens from the abomasum (fundus, corpus, and antrum), ileum, cecum, proximal loop of ascending colon, and 4 locations of the spiral colon collected from 10 healthy cows at slaughter.

PROCEDURE

Concentrations of mRNA that code for 9 subtypes of adrenergic receptors in the bovine gastrointestinal tract (alpha1A, alpha1B, alpha1D, alpha2AD, alpha2B, alpha2C beta1, beta2, and beta3) were measured by use of a quantitative real-time reverse transcription-polymerase chain reaction assay. Results were reported in relation to mRNA expression of the housekeeping gene glyceraldehyde phosphate dehydrogenase (GAPDH).

RESULTS

Mean mRNA contents of adrenergic receptors in the bovine digestive tract were low (range, 0.00006% to 5.04% of GAPDH). Distribution of receptor subtypes was similar in all tissues, with lowest expression of alpha1D receptors, followed by alpha2B, alpha2C, beta3, alpha1B, alpha1A, beta1, and beta2 in the abomasum, whereas alpha2AD and beta2 in the intestines were highest. In comparison with the intestines, relative concentrations of mRNA for receptors beta2 and beta3 were significantly lower in the abomasum.

CONCLUSIONS AND CLINICAL RELEVANCE

Relative concentrations of mRNA that code for adrenergic receptors differed among receptor subtypes and among locations in the bovine gastrointestinal tract. Comparison of these values established in healthy cattle with results for cows with motility disorders, such as abomasal displacement and cecal dilatation, may lead to improved therapeutic or prophylactic approaches for these diseases.